Clinical Trial Update: LANN-study: Lantus, Amaryl, Novorapid, Novomix Study [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for a type 2 diabetes study using Lantus, Amaryl, NovoRapid, and Novomix; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Amaryl (glimepiride)
• Lantus (insulin glargine)
• NovoRapid (insulin aspart)
• Novomix (insulin aspart protamine/insulin aspart)

Snippet

Sponsor: Rijnstate Hospital | Conditions: Diabetes Mellitus Type II | Phase 3 | Status: COMPLETED